Selective Depletion of CD20+ B Cells with A Single Course of Rituximab: Pronouced and Sustained Benefits for up to 48 Weeks in Patiens with Rheumatoid Arthritis | Charles Explorer

Selective Depletion of CD20+ B Cells with A Single Course of Rituximab: Pronouced and Sustained Benefits for up to 48 Weeks in Patiens with Rheumatoid Arthritis

Publication

Abstract

Selective Depletion of CD20+ B Cells, Rituximab, Rheumatoid Arthritis

People